Expression of female sex hormone receptors and its relation to clinicopathological characteristics and prognosis of lung adenocarcinoma
Open Access
- 15 January 2020
- journal article
- research article
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 54 (1) , 103-111
Abstract
Background: Adenocarcinoma (ADC) of the lung exhibits different clinicopathological characteristics in men and women. Recent studies have suggested that these differences originate from the expression of female sex hormone receptors in tumor cells. The aim of the present study was to evaluate the immunohistochemical expression of female sex hormone receptors in lung ADC and determine the expression patterns in patients with different clinicopathological characteristics. Methods: A total of 84 patients with lung ADC who underwent surgical resection and/or core biopsy were recruited for the present study. Immunohistochemical staining was performed for estrogen receptor alpha (ER alpha), estrogen receptor beta (ER beta), progesterone receptor (PR), epidermal growth factor receptor (EGFR), EGFR E746-A750 del, and EGFR L858R using tissue microarray. Results: A total of 39 (46.4%) ER alpha-positive, 71 (84.5%) ER beta-positive, and 46 (54.8%) PR-positive lung ADCs were identified. In addition, there were 81 (96.4%) EGFR-positive, 14 (16.7%) EGFR E746-A750 del-positive, and 34 (40.5%) EGFR L858R-positive cases. The expression of female sex hormone receptors was not significantly different in clinicopathologically different subsets of lung ADC. Conclusions: Expression of female sex hormone receptors is not associated with the prognosis and clinicopathological characteristics of patients with lung ADC.Keywords
This publication has 45 references indexed in Scilit:
- Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinomaLaboratory Investigation, 2013
- Estrogen Signaling in Lung Cancer: An Opportunity for Novel TherapyCancers, 2012
- Progesterone and estrogen receptor expression and activity in human non-small cell lung cancerSteroids, 2011
- Combined Analysis of Estrogen Receptor β-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor OutcomeClinical Cancer Research, 2011
- Estrogen receptor β and epidermal growth factor receptor as early-stage prognostic biomarkers of non-small cell lung cancerOncology Reports, 2010
- Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapyCancer and Metastasis Reviews, 2010
- Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomesCancer, 2010
- Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR MutationClinical Cancer Research, 2009
- Combined Application of 17-Estradiol and Progesterone Enhance Vascular Endothelial Growth Factor and Surfactant Protein Expression in Cultured Embryonic Lung Cells of MiceInternational Journal of Pediatrics, 2009
- Expression, function and clinical implications of the estrogen receptor (ER) beta in human lung cancersEuropean Journal of Cancer, 2001